Related Experiment Video
Updated: Dec 12, 2025
08:02
A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
Published on: March 24, 2023
4.5K
Bakuchicin attenuates atopic skin inflammation
Jae-Sung Lim1, Jun Young Kim2, Soyoung Lee3
1Cell & Matrix Research Institute, Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|August 10, 2020
Summary
Bakuchicin, a compound from Psoralea corylifolia, effectively reduced atopic dermatitis (AD) symptoms in mice and keratinocytes. This natural compound shows promise as a therapeutic agent for treating AD and related inflammatory skin conditions.
Area of Science:
- Pharmacology
- Dermatology
- Natural Products Chemistry
Background:
- Psoralea corylifolia is a medicinal herb with known therapeutic properties.
- Bakuchicin, a furanocoumarin from P. corylifolia, exhibits anti-inflammatory and anti-infective effects.
- Atopic dermatitis (AD) is characterized by inflammatory responses and lichenification.
Purpose of the Study:
- To investigate the pharmacological effects of bakuchicin on inflammatory responses and lichenification in atopic dermatitis.
- To evaluate bakuchicin's efficacy in an animal model of AD and in human keratinocytes.
Main Methods:
- An atopic dermatitis (AD)-like skin inflammation model was induced in BALB/c mice using 2,4-dinitrochlorobenzene (DNCB) and Dermatophagoides farinae (DFE) extract.
- Bakuchicin was administered intragastrically to mice, and its effects on skin inflammation, cellular infiltration, gene expression, and immunoglobulin levels were assessed.
- HaCaT keratinocytes were activated with tumor necrosis factor-α and interferon-γ to study bakuchicin's effects on cellular signaling pathways.
Main Results:
- Bakuchicin administration significantly reduced AD symptoms, including ear thickness, erythema, and keratosis in mice.
- It decreased inflammatory cell infiltration (eosinophils, mast cells) and suppressed key pro-inflammatory cytokine and chemokine gene expression (IL-4, IL-13, IL-31, IL-1β, IL-6, CXCL-1, CCL-17).
- Bakuchicin also reduced total and DFE-specific IgE and IgG2a levels and inhibited STAT-1 phosphorylation and NF-κB nuclear translocation in activated keratinocytes.
Conclusions:
- Bakuchicin demonstrates significant therapeutic potential for atopic dermatitis (AD) by attenuating key inflammatory pathways.
- These findings suggest bakuchicin as a promising natural compound for developing novel treatments for AD and similar inflammatory skin conditions.
